Document is current

Article History

Received: 5 November 2024

Revised: 12 December 2024

Accepted: 3 January 2025

First Online: 8 January 2025

Competing interests

: PR—Research funding to institution from Bayer, Lilly, Telix, Blue Earth Diagnostics, Lantheus, Novartis, Advisory board - Bayer; WX—Consulting Role: Convergent Therapeutics, PCCTC; SG—Personal honoraria for participation in <i>advisory boards</i> from Amgen, MSD; <i>other honoraria</i> from Radio-televisione Svizzera Italiana (RSI), German-speaking European School of Oncology (DESO); <i>invited speaker</i> for ESMO, Swiss group for Clinical Cancer Research (SAKK), Swiss Academy of Multidisciplinary oncology (SAMO), Orikata academy research group, <i>Speaker’s bureau</i> for Janssen Cilag; <i>travel grant</i> from ProteoMEdiX and AstraZeneca; Institutional honoraria for participation in <i>advisory boards or in Independent Data Monitoring Committees and Steering Committees</i> from AAA International, Amgen, AstraZeneca, Astellas Pharma, Bayer, Bristol-Myers Squibb, DAIICHI Sankyo, Janssen, Modra Pharmaceuticals, MSD, Myriad Genetic, Novartis, Orion, Pfizer, Roche, Telixpharma, Tolermo Pharmaceutcials; <i>invited speaker</i> for Swiss group for Clinical Cancer Research (SAKK), Cold Spring Harbor Laboratory, ASCO GU; <i>other honoraria</i> from PeerVoice, Silvio Grasso Consulting, WebMD-Medscape; Patent royalties and other intellectual property for a research method for biomarker WO2009138392; DES—Personal fees: Astellas, AstraZeneca, Bayer, Boston Scientific, GSK, Janssen, Novartis, Pfizer; PLN—research funding paid to institution: Janssen, Astellas, Bayer; Consulting: Boston Scientific, Janssen, Bayer, Novartis, Nanocan; Stock or Other Ownership: Nanocan, Stratagen Bio, Reversal Therapeutics; CJS—research funding paid to institution by Janssen, Astellas, Sanofi, Bayer; Patents, Consulting, or Advisory Role: Sanofi, Janssen, Astellas, Bayer, Genentech/Roche, Pfizer, Lilly; Hengrui; CellCentric, PointBiopharma; Royalties and other Intellectual Property: Parthenolide (Indiana University); dimethylamino parthenolide (Leuchemix); Exelixis: Abiraterone plus cabozantinib combination; FRAS1 SNP and tristetraprolin as biomarkers of lethal prostate cancer; Stock or Other Ownership: Leuchemix. All other authors declare to relevant conflicts.